ResearcherPennsylvania State UniversityActive in the last 2 years
Elizabeth Josephine Olecki
Matched on ORCID iD 0000-0002-6204-8654; OpenAlex author ID A5043479931. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2021: 5 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 7
- Epithelial-Mesenchymal Transition Is Associated With Perineural Invasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2026.09.014↗
- Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. Co-author DOI 10.1016/j.jss.2023.09.066↗
- Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. Co-author DOI 10.1002/jso.26481↗
- Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. Co-author DOI 10.1245/s10434-020-09043-y↗
- ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don't Get Fooled by Favorable Final Pathology. Co-author DOI 10.1245/s10434-020-09079-0↗
- Adjuvant Chemotherapy After Neoadjuvant Chemotherapy for Pancreatic Cancer is Associated with Improved Survival for Patients with Low-Risk Pathology. Co-author DOI 10.1245/s10434-020-09546-8↗
- ASO Author Reflection: Adjuvant Chemotherapy After Neoadjuvant Chemotherapy in Pancreatic Adenocarcinoma Does Not Lead to Improved Survival in All Patients. Co-author DOI 10.1245/s10434-021-09615-6↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Niraj Jaysukh Gusani · 5 shared papers, 2021 · strength 0.96
- Paper ASO Author Reflection: Adjuvant Chemotherapy After Neoadjuvant Chemotherapy in Pancreatic Adenocarcinoma Does Not Lead … DOI 10.1245/s10434-021-09615-6↗
- Paper ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don't Get Fooled by Favorable Final Pathol… DOI 10.1245/s10434-020-09079-0↗
- Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
- Chan Shen · 5 shared papers, 2021–2024 · strength 0.90
- Paper Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. DOI 10.1016/j.jss.2023.09.066↗
- Paper ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don't Get Fooled by Favorable Final Pathol… DOI 10.1245/s10434-020-09079-0↗
- Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
- June S. Peng · 4 shared papers, 2021–2024 · strength 0.68
- Paper Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. DOI 10.1016/j.jss.2023.09.066↗
- Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
- Paper Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. DOI 10.1002/jso.26481↗
- Matthew E. B. Dixon · 4 shared papers, 2021–2024 · strength 0.68
- Paper Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. DOI 10.1016/j.jss.2023.09.066↗
- Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
- Paper Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. DOI 10.1002/jso.26481↗
- Caleb Seavey · 1 shared paper, 2026 · strength 0.36
- Mashaal Dhir · 1 shared paper, 2026 · strength 0.36
- Asama Khan · 1 shared paper, 2026 · strength 0.36
- Kazuaki Takabe · 1 shared paper, 2026 · strength 0.36
- Madeline B. Torres · 2 shared papers, 2021 · strength 0.30
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.